Fampridine (Fampyra) for the indication ‘improvement in MS patients’ walking ability
The therapeutic value of fampridine is the same as that of pharmacy-compounded fampridine (=4-AP) in improving the walking ability of adult patients with multiple sclerosis (EDSS 4-7). Fampridine-PR has a lower therapeutic value in comparison with exercise therapy/physical therapy in improving the walking ability of adult patients with multiple sclerosis (EDSS 4-7). There is no proven place for fampridine in the therapy, neither for fampridine-PR, nor for pharmacycompounded fampridine (=4-AP).